October 19, 2018 07:13 AM EDT
R&D

#ES­MO18: Crowned with a break­through ti­tle, Clo­vis takes an ear­ly lead as it races for a fast OK for Rubra­ca in prostate can­cer

John Carroll

Editor & Founder

MU­NICH — With Lyn­parza from As­traZeneca and Mer­ck ex­pand­ing on a big lead for ovar­i­an and breast can­cer, Clo­vis On­col­o­gy $CLVS is map­ping a sep­a­rate route …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Apol­lo makes a deal worth up to $926M; Abeona re­sub­mits gene ther­a­py

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times